On Location ASH Annual Meeting
Newly Approved Drugs for AML:
How to Use Them in Practice
In 2017, the U.S. Food and Drug Admin-
istration (FDA) approved several therapies
for the treatment of hematologic malig-
nancies, including four for acute myeloid
leukemia (AML). With so many new
agents reshaping the treatment landscape,
the American Society of Hematology
(ASH) and the FDA partnered to
bring hematologists practical infor-
mation about using these agents.
At the 2017 ASH Annual Meet-
ing, experts convened for the “ASH-
FDA Joint Symposium on New Drug
Approvals in Acute Myeloid Leuke-
mia” to offer clinical and regulatory
perspectives on:
but particularly in the last year, has been
phenomenal.”
Midostaurin
Ashley Ward, MD, medical officer of the
Division of Hematology Products at the
FDA, discussed midostaurin, a multi-
targeted protein kinase inhibitor approved
for the treatment of adult patients with
newly-diagnosed FLT3 mutation-positive
AML, as well as aggressive system